J. Bennouna

Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)

IntroductionREG is a multi-kinase inhibitor that improves overall survival vs placebo in refractory mCRC. However, REG adverse tolerability profile often limits its use on normal clinica...

T. Cano ;

F. Loupakis ;

Josep Tabernero , MD, PhD;

M. Rodriguez Garrote ;

F. Herrero Rivera ;

R. Goldberg ;

J. Bennouna ;

Fortunato Ciardiello ;

A. Falcone ;

E. Aranda ;

G. Argiles ;

N. Mulet Margalef ;

M. Valladares-Ayerbes ;

J. Vieitez de Prado ;

C. Gravalos ;

P. Garcia Alfonso ;

C. Santos ;

M. Tobena ;

J. Sastre ;

M. Benavides ;

07/01/2019

A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

Background Patients with MSI-H/dMMR mCRC treated with chemotherapy have poorer outcomes than patients with microsatellite stable/MMR proficient mCRC. Pembrolizumab monot...

T. Andre ;

Sara Lonardi ;

S. Abdullaev ;

M. Lei ;

L. Jensen ;

C. De la Fouchardiere ;

E. Elez ;

J. Bennouna ;

G. Mendez ;

J. Li ;

Eric Van Cutsem , MD, PhD;

E. Goekkurt ;